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ABSTRACT 
The purpose of this thesis project was twofold. The first 
objective was to optimize the synthesis of g-methyltryptophan 
methyl ester to improve the efficiency and yield of the overall 
procedure. B-Methyltryptophan methyl ester is important in the 
synthesis of many antitumor anticancer drug candidates, including 
g-carbolines and lavendarnycin. The second objective was to 
synthesize one of these drug candidates, a new analog of 
,lavendarnycin called N-propionyllavendarnycin methyl ester. This 
compound will subsequently be tested against tumor cells in vitro 
and in vivo in hopes that it will be an effective anticancer 
agent . 
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I. S-METHYLTRYPTOPHAN METHYL ESTER 
L BACKGROUND 
The complete, efficient, stereoselective synthesis of the 
amino acid B-methyltryptophan methyl ester is important in the 
synthesis of the methyl ester of the natural anti-tumor antibiotic 
lavendamycin. Analogs of lavendamycin, and especially the N-
acetyl analogs of its methyl ester, have shown to be potent anti-
tumor agents possessing high selective toxicity against cancer 
cells. 1 
The stereochemistry of B-methyltryptophan methyl ester is 
shown below: 
+ Enantiomer + Enantiomer 
.A.. B 
Isomer A includes both the 2S,3R and 2R,3S syn enantiomers. 
Isomer B includes both the 2R,3R and 2S,3S anti enantiomers. 
There are two methods currently in the literature for the 
preparation of B-methyltryptophan methyl ester. The 
acetomidomalonate method, developed by Snyder in 1957, is rather 
long and tedious, affording only a 27% yield of mixed isomers. 3 
The nitroacetate method was first developed by Lyttle in 1947,4 
then Erofeev in 1978,5 and Rao in 1984,6 but none of the three were 
stereoselective and yielded diastereomeric mixtures of A and B 
47%. Finally in 1988 the nitroacetate method was modified by 
Behforouz through the isolation of an isomer and a change in 
catalyst to improve the yield to 71% from indole of pure isomer A.7 
1 
The emphasis on the production of pure isomer A is due to the 
dependence of the Pictet-Spengler condensation on the 
stereochemistry of g-methyltryptophan methyl ester. 8 The proposed 
mechanism of the condensation requires that the most acidic 
hydrogen of the pi-excessive indole ring system attacks the 
aldamine complex to form an intermediate five-membered ring. It 
is important that both the methyl and the methyl ester groups are 
pinned back so as not to stericly hinder this attack. Whether it 
is the 2S,3R or 2R,3S enantiomer is not important, just that it is 
in the syn conformation. 
Therefore, a simple stereoselective synthesis with high 
yields of isomer A will greatly provide for the rapid and 
efficient synthesis of lavendamycin methyl ester analogs against 
cancer. The optimization of that synthesis is reported here. 
2 
-~ RESULTS AND DXSCUSSXON 
SYNTHZSXS O~ (2RS,3SR)-2-AMXNO-3-(3-XNDOLYL) BUTANOXC ACXD 
METHYL ESTER (S-METHYLTRYPTOPHAN METHYL ESTER) 
The major objective of this part of the project was to 
optimize the synthesis of B-methyltryptophan methyl ester to 
improve the efficiency and the yield of the overall procedure. 
There were two particular steps that needed attention, the 
crystalization of the nitro compound (5) and the formation of an 
unwanted nickel salt in the final product (6). These will be 
elaborated on in the following discussion of the procedure. 
3-(IsoprQPylaroinoetbylidene)indole (3) 
The process begins with the reaction of indole (1) with 
ethylideneisopropylamine (2). The reaction is proposed to proceed 
through electrophillic attack on the double bond by the most 
reactive proton on the pi excessive indole ring system. This is 
an exothermic reaction requiring slow addition and an ice bath to 
keep the temperature below 15°C. Purification affords light brown 
crystals of (3) 70%. 
Metbyl(2RS.3SR)-2-nitro-3-(3-indolyl)butanoate (5) 
The next step is the exchange of the isopropylaminoethylidene 
group with methyl nitroadetate. This is proposed to proceed by 
the formation of the methyl nitroacetate carbocation facilitated 
by the triethylamine. This carbocation provides a proton to the 
nitrogen of the isopropylamine , making it a good leaving group, 
and allowing nucleophilic substitution to proceed. 
The crystallization of the final nitro compound proved 
difficult because this is the step where stereochemistry is 
introduced into the reaction. It turns out that when the ratio of 
the isomers A & B (as labeled in the BACKGROUND section) is near 
equal in the reaction mixture, a thick, dark residue forms rather 
than the desired off-white crystals. The first attempts to solve 
this problem included changing reaction conditions such as 
temperature, temperature ramp, and time, but no consistent change 
was seen. Next a lower percentage of hydrochloric acid was used 
3 
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to acidify the reaction mixture (10% to 5%). This was helpful, 
but did not solve the problem. 
Finally, it was discovered that by redissolving the residue 
in a chloroform hexane and then reevaporating it three times, the 
ratio of isomers changed with each successive evaporation to yield 
more of isomer A. This can be followed nicely by IH NMR as shown 
below. It appears that isomer A is both less soluble than isomer 
B and slightly more stable, because not only does more isomer A 
crystalize out with each evaporation, but it does not appear to 
revert back to B when dissolved into solution again. A final 
recrystallization gives only isomer A (87%) 
! 
Methyl(2RS,3SR)-2-arnino-3-(3-indolyl)butanoate (6) 
The final reaction in the synthesis of g-methyltryptophan 
methyl ester is the reduction of isomer A of the nitro compound. 
This is a simple hydrogenation reaction using Raney Nickel 
catalyst in the presence of trifluoroacetic acid which maintains 
the stereochemistry of the reactant in the product and solely 
reduces the nitro group to an amine. 
The formation of a green nickel salt in the purification of 
the final product made separation and filtration difficult and 
yields low. It is proposed that the trifluoroacetic acid is 
strong enough to ionize the nickel metal from the catalyst to 
nickel ion, which was then forming a salt or a nickel oxide with 
the sodium carbonate previously used to basify the reaction 
mixture. This nickel salt was a green emulsion which would 
visibly trap some of the product during filtration, yet was 
virtually undissolvable. It also left green nickel complexes In 
4 
the organic layer which required large amounts of ammonium 
chloride to remove. 
The first change made was to reduce the amount of excess 
trif1uoroacetic acid from 6:1 to 2:1 to prevent nickel ion 
formation. in addition, the sodium carbonate was replaced by 
ammonium hydroxide for basifying the reaction mixture. This 
forced any nickel ion present to form an inorganic nickel 
hydroxide complex which easily dissolved in the aqueous layer, 
making a clear blue layer which was well distinguished from the 
yellow organic layer. Thus the purification was made easier and 
yields increased to 96%. 
With these two more significant changes plus other smaller 
tweaks of the procedure, a greater overall yield was achieved. 
More importantly, the synthesis was made much cleaner, 
straightforward, and thus more enjoyable once the more difficult 
steps were simplified. This affords the rapid and efficient 
synthesis of B-methy1tryptophan methyl ester, which ultimately 
improves the efficiency of synthesizing B-carbo1ines and antitumor 
antibiotic analogs such as lavendamycin methyl ester. 
5 
II. N-PROPIONXLLAVENDAMYCIN METHYL ESTER 
~ BACKGROUND 
Lavendamycin was first isolated by Doyle in 1981 from the 
fermentation broths of the bacteria Streptomyces lavendulae at 
Bristol Laboratories. 9 Lavendamycin is a dark red solid with very 
limited solubility and a structure (shown below) similar to that 
of Streptonigrin. 
o 
COOR 
o 
Like Streptonigrin, Lavendamycin is an antitumor antibiotic, 
but both have previously been unsuccesful as antitumor agents 
because of their high toxicity.10 However, more recently, the N-
acetyl analogs of lavendamycin methyl ester have shown very 
promising in vitro and in vivo selective cytotoxicity at 
unprecedented levels compared to the current antitumor agents 
available. 1 Changing the structure or the electronics of the N-
acetyl substitutions on the Lavendamycin methyl ester ring system 
may positi'Jely affect this antitumor activity by increasing 
effectiveness while decreasing toxicity. 
The first total synthesis of Lavendamycin methyl ester was by 
Kende in 1984. 11 The synthesis began with the condensation of a 
quinaldic acid with 8-methyltryptophan methyl ester to give an 
amide which was then converted to a 8-carboline ester by a 
Bischler-Napieralski condensation. 13 
6 
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A more current synthesis developed by Behforouz uses the 
Pictet-Spengler condensation to condense £-methyltryptophan methyl 
ester with various quinolinedione aldehydes to yield the final 
product in one step.12 This procedure eases the synthesis of 
Lavendamycin methyl ester analogs because the aldehyde can be 
manipulated and substituted relatively easily before condensation 
to the final product. The general condensation reaction is shown 
below: 
o 
~+ 
R,OCHNVNACHO 
o 
R3 
etn:C02R2 Pictet-Spengler ~ . I I NH -----il~~ N 2 
t 
H 
qo N I I 0;;; 
R,OCHN N"': 
o 
The synthesis of g-methyltryptophan methyl ester has been 
reported in Section 1. Here the synthesis of the N-propionyl 
substituted quinolinedione aldehyde and its condensation with £-
methyl tryptophan methyl ester is reported to yield a new analog of 
Lavendamycin methyl ester. This furthers our group's work toward 
synthesizing various analogs which may show increased activity as 
antitumor agents against cancer cells. 
' .. :- , ........ . 
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~ RESULTS AND DISCUSSION 
SYNTHESIS OF 7-PROPIONYLLAVENDAMYCIN METHYL ESTER 
The objective of this part of the project was to synthesize a 
new N-acetyl analog of lavendamycin methyl ester by the Pictet-
Spengler condensation of B-methyltryptophan methyl ester and 7-
propionamido-2-formylquinoline-5,8-dione. The aldehyde was 
synthesized first starting from 8-hydroxy-2-quinoline and then 
condensed with B-methyltryptophan methyl ester from the first part 
of this project. 
5,7-diamino·-8-hydroxy-2-methylguinoline hydrochloride (1) 
This compound was made from 8-hydroxy-2-methylquinoline by 
nitration using a combination of concentrated nitric and sulferic 
acid in an ice bath, and then reduction over Paladium charcoal in 
the presence of hydrochloric acid. Both reactions are straight 
forward and high yielding to give 90% bright orange crystals. 
5,7 Dipropionaroido-8-hydroxy-2-methylguinoline (3) 
Propionic anhydride (2) was reacted with (1) in the presence 
of sodium acetate and sodium sulfate. This produced N-propionyl 
groups at the 5 and 7 positions and often added to the 8-hydroxy 
position as well until recrystallization in methanol and water 
produced complete (3). Before recrystalization the filter cake is 
a pasty grey material, but recrystaliztion yield clean white 
crystals which are cubic in shape (89%). The reaction is 
controlled by an equilibrium such that once the first precipitate 
product is filtered off the reaction mixture can be stirred again 
to yield more product. 
7-Propionamido-2-formylguinoline-5,8-dione (5) 
The aldehyde is completed by a series of two oxidations. 
First 7-propionamido-2-methylquinoline-5,8-dione (4) is formed 
through a simple oxidation by potassium dichromate in acetic acid. 
Then the methyl group in the 2 position is oxidized to the 
aldehyde by refluxing under Argon with selenium dioxide in 1,4 
8 
-dioxane at 110°C. The final product is bright yellow with a 
needle crystal structure (79%). 
N-Propionyllayendamycin methyl ester (7) 
The Pictet-Spengler condensation of the aldehyde (5) and B-
methyltryptophan methyl ester (6) was carried out under Argon in 
refluxing xylene at 130°C. No other reagent or catalyst is 
needed, and the reaction goes to completion within 48 hrs. It can 
easily be monitored by thin layer chromatography to determine 
completion, and affords the characteristic dark red solid of 
lavendarnycin methyl ester. 
The synthesis of the new N-acetyl analog of lavendarnycin was 
a relatively simple procedure of oxidations and reductions and a 
final condensation. This serves to demonstrate the efficiency of 
the single isomer A of B-methyltryptophan methyl ester and to add 
yet another N-acetyl analog to those being tested in the search 
for an antitumor drug candidate with high cytotoxicity. 
9 
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III. EXPERIMENTAL 
1 • GENERAL EXPERIMENTAL 
REAGENTS: acetaldehyde, isopropy1amine, indole, methyl nitro 
acetate, Raney nickel catalyst, 8-hydroxy-2-methy1quino1ine, 
propionic anhydride, pa1adium charcoal, and selenium dioxide were 
all purchased from Aldrich Chemical Company. 
SOLVENTS: 1,4 dioxane, toluene, and xylene were dried and 
distilled before use. Chloroform, ethyl acetate, ethyl ether, 
dich1oromethane, hexane, and 95% ethanol were reagent grade and 
not distilled. 
MELTING RANGES: Melting ranges were recorded with a Thomas Hoover 
capillary melting point apparatus. 
THIN LAYER CHROMATOGRAPHY: TLC was performed using Eastman Kodak 
silica gel sheets with f10urescent indicator. 
NUCLEAR MAGNETIC RESONANCE (lH NMR): NMR spectra were recorded on 
a Varian Gemini 200 spectrometer in deuterated chloroform or 
deuterated dimethyl sulfoxide (DMSO) with tetramethy1 silane (TMS) 
or residual DMSO as the internal standards. 
10 
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2 • PROCEDURAL EXPERIMENTAL 
2 A. SYNTHESIS OF (2RS,3SR)-2-AMINO-3-(3-INDOLYL) BUTANOIC 
ACID METHYL ESTER (S-METHYLTRYPTOPHAN METHYL ESTER) 
Cr:) 
H H 
1 3 
er::0
H3C COCCH3 
I I NOz 
.& N 
H + Enantiomer 
5 I 
A. Ethylideneisopropylamine (2) A l-L, three-necked, round-
bottomed flask, equipped with a mechanical stirrer, dropping 
funnel, thermometer, and condenser cooled with ice-water and 
protected from moisture by a calcium chloride-filled drying tube, 
is immersed in an ice-salt bath. In the flask is placed 
isopropylamine (59.0 g, 1.0 mol). Freshly distilled acetaldehyde 
(44.0 g, 1.0 mol) is added at oOe over a period of 3 hrs with 
stirring. The colorless solution is stirred for an additional 20 
min. The reaction mixture is transferred to a SOD mL Erlenmeyer 
flask and ground potassium hydroxide flakes are added until 
separation into two layers occurs. The light-brown upper organic 
layer is separated from the dark-brown lower aqueous layer and 
allowed to stand over barium oxide in the cold room overnight. 
The resulting brown mixture is filtered to obtain the colorless 
liquid (Note 1) which is stored tightly stoppered in the 
refrigerator: 71.89 g (84 %) . 
B. 3-(Isopropylaminoethylidene)indole (3). A 1-L, three-
necked, round-bottomed flask, equipped with a mechanical stirrer, 
dropping funnel, thermometer, and condenser cooled with ice-water 
and protected from moisture by a calcium chloride-filled drying 
11 
more times to yield brown colored crystals which were 
recrystallized in the same chloroform: hexane mixture to yield 
light brown to off-white crystals of isomer A (Note 5): 22.94 g 
(87 %). 
D. Methyl(2RS,3SR)-2-Amino-3-(3-indolyl)butanoate (6). In a 
500 mL heavy-walled flask containing a magnetic stir bar is placed 
an ice cooled solution of trifluoroacetic acid (2.6 g, 22.8 mmol) 
in 150 mL absolute ethanol to which ground nitroester (4) (3.0 g, 
11.4 mmol) is added. The mixture is stirred for 30 min to 
dissolve most of the solid. The magnetic stir bar is removed and 
9 g of commercial Raney nickel catalyst is added after having been 
rinsed with absolute ethanol (3 x 50 mL). Hydrogenation is 
carried out at 40 psi (2.75 atm) at room temperature until 
hydrogen absorption ceased (1 hour). The reaction mixture is 
filtered carefully through a layer of celite (Note 6) and the 
filter cake washed with absolute ethanol (3 x 50 mL). The 
filtrate is then evaporated to yield a yellow-green liquid. To 
this material 100 mL ether, 50 mL water, and 15 mL 14 % ammonium 
hydroxide were added. The yellow upper ether layer is separated 
from the blue lower aqueous layer and saved. The aqueous layer is 
extracted with ether (4 x 50 mL) and the ether extracts are 
combined with the previous ether layer and washed with water (1 x 
100 mL) and 10 % ammonium chloride (2 x 100 mL) (Note 7). After 
drying over magnesium sulfate, the ether is evaporated to give 
off-white crystals (Note 8): (2.53 g. 96 %). 
NOTES 
1. Distillation is not necessary since the liquid is 
generally very pure. If distillation is desired, it should be 
carried out under very low heat and vacuum of about 125 mm Hg. 
2. Purification is difficult and yield low when previously 
opened or less than 99 % pure indole is used. 
3. Methyl nitroacetate is commercially available but 
expensive. It can easily be prepared by the method found in 
J.Heterocyclic.Chem., 1988, 25, 1627. 
4. The liberation of isopropylamine can be checked with pH 
paper during the process. 
5. The desired isomer A appears to be more stable than 
13 
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isomer B, such that repeated evaporations and a final 
recryst~llization promote the conversion between isomers favoring 
isomer A. As the ratio of isomers changes with successive 
treatments, the residue changes from a thick, dark, oily substance 
to the desired brown crystals. 
6. Caution! Care must be taken in filtering to prevent the 
Raney nickel catalyst filter cake from becoming dry and igniting. 
7. If green color persists, continue washing with ammonium 
chloride to remove any remaining nickel salt. 
14 
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2B.SYNTHESIS OF 7-PROPIONAMIDO-2-FORMYLQUINOLINE-S,8-DIONE 
HAc .. 
.. 
5 
A. 5,7 Diamino-B-hydroxy-2-methylquinoline hydrochloride 
(1). In a 500-mL heavy-walled flask is placed 100 mL water and 13 
mL concentrated hydrochloric acid to which 5,7-dinitro-8-hydroxy-
2-methylquinoline (6.23 g, .025 mol) and 1 g Paladium charcoal 
catalyst are added. Hydrogenation is carried out at 30 psi 
overnight (about 15 hrs.). The reaction mixture is then filtered 
to remove the catalyst, and the filter cake washed with water (3 x 
100 mL). The orange-red filtrate is evaporated and the solid 
dried under vacuum overnight to yield bright orange crystals: 5.90 
g (90%). 
B. 5,7 Dipropionamido-B-hydroxy-2-methylquinoline (3). In a 
125-mL Erlenmeyer flask equipped with magnetic stir bar is placed 
5,7-diamino-8-hydroxy-2-methylquinoline hydrochloride (1.0 g, 
.0038 mol) dissolved in a minimum amount of water. While 
stirring, the following are added in rapid succession: sodium 
sulfite (2.40 g, .019 mol), sodium acetate (3.10 g, .023 mol), and 
propionic anhydride (12.37 g, .095 mol). The solution is stirred 
for an additional 3 hrs. and the white precipitate filtered off, 
washed with water. The resulting pasty filter cake is 
recrystallized in methanol and water and dried under vacuum to 
yield white crystals (Note 1): 1.02 g (89%). 
C. 7-Propionamido-2-methylquinoline-5,B-dione (4). In a 
250-mL Erlenmeyer flask is suspended 5,7-dipropionamido-8-hydroxy-
2-methylquinoline (.66 g, .0017 mol) in 32 mL glacial acetic acid. 
15 
-To this a solution of potassium dichromate (2.4 g, .008 mol) in 32 
mL water is added and the mixture stirred for an additional 2 hrs 
(Note 2). 20 mL dichloromethane is then added and the mixture 
allowed to stir overnight. The resulting solution is washed with 
dichloromethane (12 x 25 roL), the organic layers combined and 
washed with 3% sodium bicarbonate (2 x 50 roL). The yellow 
solution is then dried over magnesium sulfate and evaporated to 
yield bright yellow crystals: .290 g (69%). 
D. 7-Propionamido-2-formylquinoline-5,B-dione (5). In a 50-
mL round bottom flask equipped with magnetic stir bar, water 
cooled condenser, Argon filled balloon, and immersed in an oil 
bath is placed 7-propionamido-2-methylquinoline-5,8-dione (.200 g, 
.0008 mol) and selenium dioxide (.12 g, .001 mol) in 10 roL freshly 
distilled 1,4 dioxane and 3 drops of water (Note 3). The reaction 
mixture is heated to 110°C over 1 hour and allowed to reflux for 
an additional 25 hrs., monitored for completion by thin layer 
chromatography. The mixture is filtered hot to remove the 
selenium metal which is rinsed in hot 1,4 dioxane (5 x 20 mL). 
The filtrates are stored overnight at 4°C. After adding 100 mL 
dichloromethane, the solution is washed with 3% sodium bicarbonate 
(2 x 100 mL), dried over magnesium sulfate, and evaporated to 
yield yellow crystals: .169 g (79%). 
NOTES 
1. After filtering off the original precipitate, further 
stirring of the filtrate often leads additional product. 
2. The reaction mixture begins as an orange suspension but 
changes to a uniformly dark and clear solution. 
3. The 1,4 dioxane must be freshly distilled. It is the 
purity of the solvent, not necessarily the dryness, which is 
important in this reaction. With an impure solvent the reaction 
does not go to completion. 
,-
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2 C. SYNTHESIS OF 7 -N-PROPIONYLLAVENDAMYCIN METHYL ESTER 
o 
In a SO-mL round bottom flask equipped with magnetic stir 
bar, water cooled condenser, Argon filled balloon, and immersed in 
an oil bath, is placed B-methyltryptophan methyl ester (.05 g, 
.0002 mol) and 7-propioamido-2-formylquinoline-5,8-dione (.055 g, 
.00025 mol) in 20 mL freshly distilled xylene. The solution is 
heated to 130°C and allowed to reflux for 48 hrs. while reaction 
progress is monitored by thin layer chromatography. The resulting 
reaction mixture is filtered hot to remove the precipitate, and 
the filtrate evaporated to yield dark red crystals. 
17 
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